source
- Novartis' pelacarsen fails Phase 3, casting doubt on Lp(a) lowering strategyNovartis announced that its antisense drug pelacarsen failed to meet the primary endpoint in the Phase 3 Lp(a)HORIZON trial. The study was intended to determine whether the drug’s ability to lower…
- Benelux’s strong science base eyed for biotech scaling despite funding gapsBelgium and the Netherlands have built some of Europe’s strongest life‑science ecosystems, anchored by leading research institutions and a growing pool of biotech talent. Early‑stage capital remai…